BRCA1 and familial pancreatic carcinoma: Tobalina et al. reported a meta-analysis including 327 BRCA1/BRCA2 mutant patients with ovarian cancer, breast cancer, pancreatic cancer or prostate cancer, who progressed on platinum-based or PARP inhibitor treatment.